Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
16
16 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- TDVTAK-003, Tetravalent Dengue VaccinePhase 35 trials
Takeda · Dengue Fever, Healthy Volunteers
- MezagitamabTAK-079Phase 34 trials
Takeda · Immune Thrombocytopenic Purpura (ITP), Antibody-Mediated Rejection (AMR), Kidney Disease
- TAK-360Phase 34 trials
Takeda · Narcolepsy Type 1, Idiopathic Hypersomnia, Narcolepsy Type 2
- FazirsiranTAK-999, ARO-AATPhase 33 trials
Takeda · Alpha1-Antitrypsin Deficiency
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- TAK-771Phase 32 trials
Takeda · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Primary Immunodeficiency Diseases (PID)
- TAK-330Phase 31 trial
Takeda · Coagulation Disorder
- TAK-928Phase 31 trial
Takeda · IO Resistant Squamous and Nonsquamous NSCLC
- TAK-007Phase 21 trial
Takeda · Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- TAK-101Phase 21 trial
Takeda · Celiac Disease
- TAK-188Phase 21 trial
Takeda · Advanced or Metastatic Solid Tumors
- TAK-341MEDI1341Phase 21 trial
Takeda · Multiple System Atrophy
- TAK-411Hypersialylated Immune Globulin GPhase 21 trial
Takeda · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- TAK-505Phase 21 trial
Takeda · Malignant Solid Tumors
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.